Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Roche Holding AG is a Swiss multinational holding company and one of the world's largest biotech firms, overseeing the operations of F. Hoffmann-La Roche AG, a leading provider of pharmaceuticals and in-vitro diagnostics. Founded in 1896 and headquartered in Basel, it drives innovation across major disease areas including oncology, neuroscience, ophthalmology, infectious diseases, and rare conditions through its two primary divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops innovative medicines targeting cancer, haemophilia, and inflammatory diseases, while Diagnostics produces equipment and reagents for clinical research, molecular testing, and patient monitoring. Roche Holding AG maintains a robust research and development pipeline with 76 projects in scope for access-to-medicine initiatives, emphasizing priority areas like hepatitis B and antibacterial-resistant infections, complemented by a portfolio of 118 products including WHO-listed medicines and diagnostics. Notable for wide product registration in low- and middle-income countries and programs like the Global Access Programme serving 89 nations, it plays a pivotal role in global healthcare by integrating diagnostics with therapies to advance patient outcomes and access.
Margins and capital returns are both well above average: 29.16% operating margin, ROIC at 20.92%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue growth slowed to 1.5%, essentially flat. This is a business that needs a catalyst.
Free cash flow declined 13% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
CHF 63.36B
▲ +1.5% YoY
Net Income (TTM)
CHF 13.80B
▲ +50.2% YoY
Op. Margin
29.16%
▲ +7.7pp YoY
ROIC
20.92%
▲ +5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
CHF 13.07B
▼ -13.3% YoY
Op. Cash Flow (TTM)
CHF 15.99B
▼ -13.8% YoY
Net Debt
CHF 17.71B
Cash & Equiv.
CHF 15.48B
3Y CAGR: -1.3%
3Y CAGR: -0.4%
Continue Research